EP0767659A1 - Transdermal administration of oxybutynin - Google Patents

Transdermal administration of oxybutynin

Info

Publication number
EP0767659A1
EP0767659A1 EP93911284A EP93911284A EP0767659A1 EP 0767659 A1 EP0767659 A1 EP 0767659A1 EP 93911284 A EP93911284 A EP 93911284A EP 93911284 A EP93911284 A EP 93911284A EP 0767659 A1 EP0767659 A1 EP 0767659A1
Authority
EP
European Patent Office
Prior art keywords
oxybutynin
skin
reservoir
permeation enhancer
permeation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP93911284A
Other languages
German (de)
French (fr)
Other versions
EP0767659B1 (en
Inventor
Eun Soo Lee
Diane E. Nedberge
Su Il Yum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of EP0767659A1 publication Critical patent/EP0767659A1/en
Application granted granted Critical
Publication of EP0767659B1 publication Critical patent/EP0767659B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • This invention relates the efficacious and safe, controlled transdermal administration of oxybutynin and related compounds for s the treatment of neurogenic bladder disorders.
  • Neurogenic bladder disease is a disorder involving loss of control of urination.
  • the major symptoms of this disease are urinary frequency, urinary retention or incontinence.
  • the second lesion, a lower motoneuron lesion involves hypotonia and hyporeflexia of the bladder.
  • the major symptoms in s this condition are urinary retention, since the voiding reflex has been lost, and incontinence, which occurs when the bladder "leaks", being full to overflowing.
  • the majority of neurogenic bladder patients have the spastic or hypertonic bladder.
  • the clinician usually attempts to convert the 0 condition of hyperreflexia and hypertonia to hypotonia, thereby treating the primary problem of incontinence.
  • hypotonia When the condition has .been converted to hypotonia, it can be managed by intermittent catheterization.
  • there is a significant population of patients who cannot be converted completely from the hypertonic to 5 the hypotonic condition, and who still find they have to urinate every hour or are incontinent. For these patients, treatment with an anticholinergic drug is necessary.
  • the drug of choice is oxybutynin (4-diethylamino-2-butynylphenylcyclohexylglycolate).
  • Oxybutynin chloride is normally administered to human beings orally at relatively high doses (5 mg tablets taken two to four times a day).
  • Oxybutynin has been incorporated into tablets, capsules, granules or pills containing 1-5 mg, preferably 5 mg, of oxybutynin chloride, syrups containing 1-5 mg, preferably 5 mg, of oxybutynin chloride per 5 ml and transdermal compositions (creams or ointments) containing 1-10 weight percent ("wt %") oxybutynin chloride. See, BE 902605.
  • oxybutynin was listed as an agent that could be incorporated into a transdermal synthetic resin matrix system for extended duration drug release, but oxybutynin was not used in the device.
  • oxybutynin was given as a pharmacologically active agent suitable for transdermal delivery, but as with the above reference, oxybutynin was not incorporated into the device.
  • Oxybutynin has been incorporated into a device having a water impermeable barrier layer, a reservoir containing oxybutynin in contact with the inner surface of the barrier layer and a removable protector layer in contact with the other surface of the reservoir.
  • the reservoir is a polyurethane fiber mat impregnated with an aqueous solution containing 25 mg/ml of oxybutynin.
  • the device was placed on a 20 jtim thick polybutadiene film.
  • the non-device carrying surface was in contact with 0.05 M isotonic phosphate buffer solution.
  • the in vitro release rate measured was approximately 12 mg over 24 hours through a 49 cm 2 area or 10 ⁇ g/cm 2 /hr.
  • permeation enhancers for transdermal administration is described in numerous technical publications and patents, such as U.S. Patents Nos. 4,940,586;
  • Permeation enhancers that are not normally toxic at the concentrations employed in cosmetic or medical compositions may exhibit toxic effects at the higher concentrations required to produce adequate permeation enhancement.
  • No "universal" permeation enhancer has been identified. Instead, the behavior of permeation enhancers is highly idiosyncratic; a permeation enhancer effective for one drug may not be effective with other drugs, including closely related drugs. Often, a permeation enhancer will exacerbate irritation and sensitization problems by allowing high transdermal permeation rates of the drug or permeation enhancer or permitting otherwise impermeable components of the transdermal device to enter the skin.
  • permeation enhancers interact adversely with other components of transdermal devices.
  • One major problem is that many potential permeation enhancers are not compatible with medically acceptable contact adhesives. Enhancers may improve the transdermal permeation rate adequately, but not adequately reduce the lag time.
  • Enhancers may improve the transdermal permeation rate adequately, but not adequately reduce the lag time.
  • the use of a permeation enhancer in any transdermal drug delivery device necessarily complicates the design and development of the device.
  • Permeation enhancers cause compatibility problems throughout the delivery system. Instead of having to characterize the properties of the reservoir compositions, adhesives, and release- controlling materials with respect to just the drug, these materials must now have the proper characteristics with respect to both the drug and the permeation enhancer.
  • drugs and permeation enhancers have very different physical and chemical properties, and, in most cases, the properties of mixtures of the drug with the permeation enhancer are unknown.
  • permeation enhancers can cause, among other problems, cohesive failure of adhesives and can partition through other components in the system.
  • oxybutynin is used to designate oxybutynin, acid addition salts of oxybutynin and the related compounds thereof.
  • the preferred active agent according to the present invention is oxybutynin itself.
  • Oxybutynin is a base capable of forming acid addition salts with organic and mineral acids, for example, with hydrochloric acid to form oxybutynin chloride.
  • the device of this invention contains oxybutynin as the free base.
  • transdermal delivery or application refers to the delivery or application of oxybutynin by passage through skin, mucosa and/or other body surfaces by topical application.
  • the term "therapeutically effective" amount or rate refers to the amount or rate of oxybutynin needed to effect the desired therapeutic result.
  • the term “monoesters” refers to those monoesters having from 10 to 20 carbon atoms.
  • the term “glycerol monooleate” refers to glycerol monooleate itself or a mixture of monoglycerides wherein glycerol monooleate is present in the greatest amount.
  • glycerol monolaurate refers to glycerol monolaurate itself or a mixture of monoglycerides wherein glycerol monolaurate is present in the greatest amount.
  • glycerol onolinoleate refers to glycerol monolinoleate itself or a mixture of monoglycerides wherein glycerol monolinoleate is present in the greatest amount.
  • oxybutynin may be safely and efficaciously administered transdermally, together with a suitable permeation enhancer, preferably a monoglyceride or mixture of monoglycerides of fatty acids with a total monoester content of at least 51%.
  • a suitable permeation enhancer preferably a monoglyceride or mixture of monoglycerides of fatty acids with a total monoester content of at least 51%.
  • the invention includes a transdermal drug delivery device containing sufficient amounts of permeation enhancer and of oxybutynin, in combination, to provide systemic administration of oxybutynin through the skin for a predetermined period of time for the oxybutynin to provide an effective therapeutic result.
  • FIG. 1 is a cross-section through a schematic perspective view of one embodiment of transdermal therapeutic devices according to this invention.
  • FIG. 2 is a cross-section through another embodiment of a transdermal therapeutic device according to this invention.
  • FIG. 3 is a cross-section through another embodiment of a transdermal therapeutic device according to this invention.
  • FIG. 4 is a cross-section through yet another embodiment of a transdermal therapeutic device according to this invention.
  • FIG. 5 shows the oxybutynin permeation rate through the epidermis at 35 ⁇ C with various permeation enhancers.
  • oxybutynin may be administered to the human body in a therapeutically effective amount via the transdermal route when it is co-administered with a suitable permeation enhancer.
  • Therapeutic blood levels from DUt 0.5 ng/ml to about 3.0 ng/ml can be obtained from administration rates in the range of 0.08 mg/hr to 0.5 mg/hr.
  • Representative skin permeation rates of oxybutynin through living human skin are in the range of about 12 ⁇ g/cm 2 /hr to about 40 ⁇ g/cm 2 /hr, depending on the permeation enhancer.
  • Therapeutic blood levels can be achieved within approximately 1-5 hours, and peak blood concentrations are achieved at about 3 hours when the system is worn for 24 hours.
  • the range of desired and achievable system permeation rates of oxybutynin, arriving through the skin from a limited area is 1-20 mg over a period of 24 hours.
  • the system application is easily adapted for shorter or longer duration treatments, but generally 24 hours is the nominal duration for treatment.
  • transdermal delivery devices are described in U.S. patent numbers 3,598,122; 3,598,123; 4,286,592; 4,314,557; 4,379,454; 4,559,222; 4,573,995; and 4,849,226, for example. All of these are incorporated herein by reference.
  • the co-administration of oxybutynin and a permeation enhancer as disclosed herein can be accomplished by using transdermal devices of these kinds.
  • oxybutynin and the permeation enhancer be administered from a rate-controlled transdermal delivery device.
  • Rate control can be obtained either through a rate-controlling membrane or adhesive or through the other means disclosed in the patents noted above.
  • a certain amount of oxybutynin will bind to the skin, and it is accordingly preferred that the skin-contacting layer of the device include this amount of the agent as a loading dose.
  • FIGS. 1, 2 and 3 Examples of suitable transdermal delivery devices are illustrated in FIGS. 1, 2 and 3.
  • the same reference numbers are used throughout the different figures to designate the same or similar components. The figures are not drawn to scale.
  • transdermal delivery device 10 comprises a reservoir 12 containing both oxybutynin and a suitable permeation enhancer.
  • Reservoir 12 is preferably in the form of a matrix containing oxybutynin and enhancer dispersed therein.
  • Reservoir 12 is sandwiched between a backing layer 14, which is permeable to water vapor, and an in-line contact adhesive layer 16.
  • the backing is a spun-laced polyester, such as Sontara®, a nylon reinforced polyurethane, such as NRU-100-C Flexcon ® or a multilaminate film layer, such as EVA/EVA/polyvinyldienefluoride
  • the device 10 adheres to the surface of the skin 18 by means of the adhesive layer 16.
  • the adhesive layer 16 may optionally contain enhancer and/or oxybutynin.
  • a strippable release liner (not shown in FIG. 1) is normally provided along the exposed surface of adhesive layer 15 and is removed prior to application of device 10 to the skin 18.
  • a rate- controlling membrane (not shown) may be present between the reservoir 12 and the adhesive layer 16.
  • transdermal therapeutic device 20 may be attached to the skin or mucosa of a patient by means of an adhesive overlay 22.
  • Device 20 is comprised of a oxybutynin- and permeation enhancer-containing reservoir 12 which is preferably in the form of a matrix containing oxybutynin and the enhancer dispersed therein.
  • Adhesive overlay 22 maintains the device on the skin and may be fabricated together with, or provided separately from, the remaining elements of the device. With certain formulations, the adhesive overlay 22 may be preferable to the in-line contact adhesive 16 as shown in FIG. 1.
  • the oxybutynin/enhancer reservoir contains a material which adversely affects the adhesive properties of the in ⁇ line contact adhesive layer 16.
  • Backing layer 14 is preferably slightly larger than reservoir 12, and in this manner prevents the materials in reservoir 12 from adversely interacting with the adhesive in overlay 22.
  • a rate-controlling membrane (not shown in FIG. 2) may be provided on the skin-proximal side of reservoir 12.
  • a strippable release liner 24 is also provided with device 20 and - * s removed just prior to application of device 20 to the skin.
  • transdermal del very device 30 comprises a oxybutynin and permeation enhancer containing reservoir (“oxybutynin reservoir”) 12 substantially as described with respect to FIG. 1.
  • Permeation enhancer reservoir (“enhancer reservoir”) 26 comprises permeation enhancer dispersed throughout and is substantially free of any undissolved oxybutynin.
  • Enhancer reservoir 26 is preferably made from substantially the same matrix as is used to form oxybutynin reservoir 12.
  • a rate-controlling membrane 28 for controlling the release rate of the permeation enhancer from enhancer reservoir 26 to oxybutynin reservoir 12 is placed between the two reservoirs.
  • a rate-controlling membrane (not shown in FIG.
  • the rate-controlling membrane may be fabricated from permeable, semipermeable or microporous materials which are known in the art to control the rate of agents into and out of delivery devices and having a permeability to the permeation enhancer lower than that of oxybutynin reservoir 12. Suitable materials include, but are not limited to, polyethylene, polyvinyl acetate and ethylene vinyl acetate copolymers.
  • a backing 14 Superimposed over the permeation enhancer reservoir 26 of device 30 is a backing 14 that is permeable to water vapor.
  • an adhesive layer 16 On the skin-proximal side of reservoir 12 are an adhesive layer 16 and a strippable liner 24 which would be removed prior to application of the device 30 to the skin.
  • the carrier or matrix material of the reservoirs has sufficient viscosity to maintain its shape without oozing or flowing. If, however, the matrix or carrier is a low viscosity flowable material such as a liquid or a gel, the composition can be fully enclosed in a pouch or pocket, as known to the art from U.S. Pat. No. 4,379,454 (noted above), for example, and as illustrated in FIG. 4.
  • Device 40 shown in FIG. 4 comprises a backing member 14 which serves as a protective cover for the device, imparts structural support, and substantially keeps components in device 40 from escaping the device.
  • Device 40 also includes reservoir 12 which contains the oxybutynin and permeation enhancer and bears on its surface distant from backing member 14 a rate-controlling membrane 28 for controlling the release of oxybutynin and/or permeation enhancer from device 40.
  • the outer edges of backing member 14 overlay the edges of reservoir 12 and are joined along the perimeter with the outer edges of the rate-controlling membrane 28 in a fluid-tight arrangement.
  • This sealed reservoir may be effected by pressure, fusion, adhesion, an adhesive applied to the edges, or other methods known in the art.
  • reservoir 12 is contained wholly between backing member 14 and rate-controlling membrane 28.
  • On the skin-proximal side of rate-controlling membrane 28 are an adhesive layer 16 and a strippable liner 24 which would be removed prior to application of the device 40 to the skin.
  • reservoir 12 contains the permeation enhancer only and is s substantially free of oxybutynin.
  • the oxybutynin and an additional amount of permeation enhancer are present in adhesive layer 16 which acts as a separate reservoir.
  • the oxybutynin and the permeation enhancer can be co-extensively administered to human skin or mucosa by direct
  • Aqueous formulations typically comprise water or water/ethanol and about 1-2 wt % of a gelling agent, an example being a hydrophilic polymer
  • Typical non-aqueous gels are comprised of silicone fluid or mineral oil.
  • Mineral oil-based gels also typically contain 1-2 wt % of a gelling agent such as colloidal silicon dioxide. The suitability of a particular gel depends upon the compatibility of its constituents
  • the reservoir matrix should be compatible with oxybutynin, the permeation enhancer and any carrier therefor.
  • matrix refers to a well-mixed composite of ingredients fixed
  • the reservoir matrix is preferably a hydrophilic polymer, e.g., a hydrogel .
  • the reservoir matrix is preferably composed of a hydrophobic polymer. Suitable polymeric matrices are well known in the transdermal drug delivery art, and examples are listed in the above-named patents previously incorporated herein by reference.
  • a typical laminated system would comprise a polymeric membrane and/or matrix such as ethylene vinyl acetate (EVA) copolymers, such as those described in U.S. Pat. No. 4,144,317, preferably having a vinyl acetate (VA) content in the range of from about 9% up to about 60% and more preferably about 28% to about 60% VA.
  • EVA ethylene vinyl acetate
  • VA vinyl acetate
  • Polyisobutylene/oil polymers containing from 4-25% high molecular weight polyisobutylene and 20-81% low molecular weight polyisobutylene with the balance being an oil such as mineral oil or polybutynes may also be used as the matrix material.
  • the amount of oxybutynin present in the therapeutic device and required to achieve an effective therapeutic result depends on many factors, such as the minimum necessary dosage of oxybutynin for the particular indication being treated; the solubility and permeability of the matrix, of the adhesive layer and of the rate-controlling membrane, if present; and the period of time for which the device will be fixed to the skin.
  • the minimum amount of oxybutynin is determined by the requirement that sufficient quantities of oxybutynin must be present in the device to maintain the desired rate of release over the given period of application.
  • the maximum amount for safety purposes is determined by the requirement that the quantity of oxybutynin present cannot exceed a rate of release that reaches toxic levels.
  • the oral lethal dose discovered for rats is 1220 mg/kg.
  • the oxybutynin When a constant oxybutynin delivery rate is desired, the oxybutynin is normally present in the matrix or carrier at a concentration in excess of saturation, the amount of excess being a function of the desired length of the oxybutynin delivery period of the system.
  • the oxybutynin may, however, be present at a level below saturation without departing from this invention as long as oxybutynin is continuously administered to the same skin or mucosa site in an amount and for a period of time sufficient to provide the desired therapeutic rate and delivery profile of oxybutynin delivery.
  • the permeation enhancer is dispersed through the matrix or carrier, preferably at a concentration sufficient to provide permeation-enhancing amounts of enhancer in the reservoir throughout the anticipated administration period. Where there is an additional, separate permeation enhancer matrix layer as well, as in FIGS. 3 and 4, the permeation enhancer normally is present in the separate reservoir in excess of saturation.
  • the preferred permeation enhancers of the present invention are a onoglyceride or a mixture of monoglycerides of fatty acids with a total monoester content of at least 51%.
  • Fatty acids may be saturated or unsaturated and straight or chained, and include, for example, 1auric acid, myristic acid, stearic acid, oleic acid, linoleic acid and palmitic acid.
  • Monoglycerides are generally available as a mixture of monoglycerides, with the mixture deriving its name from the monoglyceride present in the greatest amount.
  • Monoglyceride permeation enhancers include, for example, glycerol monooleate, glycerol monolaurate and glycerol monolinoleate.
  • the permeation enhancer is glycerol monooleate.
  • the matrix or carrier may also contain dyes, pigments, inert fillers, excipients and other conventional components of pharmaceutical products or transdermal devices known to the art.
  • oxybutynin is delivered at a therapeutically effective rate (that is, a rate that provides a desired therapeutic effect) and the permeation enhancer is delivered at a permeation-enhancing rate (that is, a rate that provides increased permeability of the application site to the oxybutynin) for a predetermined time period and in the required delivery pattern.
  • a therapeutically effective rate that is, a rate that provides a desired therapeutic effect
  • the permeation enhancer is delivered at a permeation-enhancing rate (that is, a rate that provides increased permeability of the application site to the oxybutynin) for a predetermined time period and in the required delivery pattern.
  • a preferred embodiment of the present invention comprises a method of treating any disorder in which it is therapeutic to administer a therapeutically effective amount of one or more of the compounds of the present invention to a patient suffering from such disorder.
  • Another preferred embodiment of the present invention comprises a method of treating neurogenic bladder disorders, e.g., urinary frequency or incontinence.
  • oxybutynin should be present in plasma at levels above about 0.5 ng/ml, preferably at levels above about 1.0 ng/ml and most preferably at levels of about 2.0 ng/ml.
  • oxybutynin is delivered at a therapeutic rate of at least about 40-200 ⁇ g per hour, but typically of at least 80 ⁇ g/hr, and more typically at about 80-160 ⁇ g/hr, for the treatment period, usually about 24 hours to 7 days.
  • the administration rate through the skin should be sufficient to minimize the size of the device.
  • the size of the device of this invention can vary from less than 1 cm 2 to greater than 200 cm 2 . typical device, however, will have a size within the range of 5-50 cm 2 .
  • the delivery device containing the oxybutynin and a permeation enhancer is placed on a user such that the device is delivering oxybutynin in a therapeutically effective amount to the user to treat a neurogenic bladder disorder.
  • the length of time of oxybutynin presence and the total amount of oxybutynin in the plasma can be changed following the teachings of this invention to provide different treatment regimens. Thus, they can be controlled by the amount of time during which exogenous oxybutynin is delivered transdermally to an individual or animal.
  • the devices of this invention can be designed to effectively deliver oxybutynin for an extended time period of from several hours up to 7 days or longer. Seven days is generally the maximum time limit for application of a single device because the adverse affect of occlusion of a skin site increases with time and the normal cycle of sloughing and replacement of the skin cells occurs in about 7 days.
  • the transdermal therapeutic devices of the present invention are prepared in a manner known in the art, such as by those procedures, for example, described in the transdermal device patents listed previously herein. Having thus generally described the invention, the following specific examples describe preferred embodiments thereof.
  • Example 1 The devices for Example 1 were prepared as follows: A. Formulation without a Permeation Enhancer
  • a formulation containing 30 wt % oxybutynin base in a matrix of EVA 40 (U.S.I. Chemicals, Illinois) was prepared by dissolving the oxybutynin base and EVA 40 in methylene chloride. The solution was poured onto a sheet of fluorocarbon diacrylate ("FCD")/polyester release liner to dry. The dried material was pressed to 5 mil (a. 0.1 mm) thickness between two sheets of FCD/polyester release liner at 75"C. The resulting film was laminated to a flexible cloth backing (spun laced polyester, 1.3 oz/yd 2 ), and 2.0 cm 2 discs were cut from the laminate.
  • FCD fluorocarbon diacrylate
  • Formulations containing oxybutynin base at 30 wt %, and various permeation enhancers glycerol monolaurate, glycerol monooleate, and glycerol monolinoleate) at 25 wt % in a matrix of EVA 40 were prepared by dissolving the oxybutynin base, permeation enhancer and EVA 40 in methylene chloride. The same procedure as described above was then used to make the device.
  • the glycerol monooleate (GM0) used was Myverol ® 18-99K glycerol monooleate (Eastman Kodak Chemicals), which has a glycerol monooleate content of 61% and a total monoester content of 93%
  • the glycerol monolinoleate (GMLO) used was Myverol ® 18-92K glycerol monolinoleate, which has a glycerol monolinoleate content of 68% and a minimum total monoester content of 90%
  • the glycerol monolaurate (GML) used was Grindtek ® ML 90 glycerol monolaurate, which has a glycerol monolaurate content of 90% and a minimum total monoester content of 90%.
  • each of the oxybutynin matrix/cloth backing laminates were divided in half, and one half of each was laminated to 3M acylate transfer adhesive MSP 32589 (1.6 mil, an acrylate adhesive with 2-5% acid functionality). Before testing, each final laminate was equilibrated for at least 5 days to allow the enhancer and oxybutynin to partition into the contact adhesive. The edges of the devices with in-line adhesive were masked with polyester tape so that the oxybutynin reservoir edges were not exposed to the epidermis or solutions when they were tested.
  • Formulation containing GMO A formulation containing 27 wt % oxybutynin base and 27 wt % GMO (Myverol ® 18-99K glycerol monooleate) in a matrix of EVA 40 was prepared using a Brabender Mixer and a 50 cc mixing bowl. The EVA 40 was added to the mixing bowl and mixed until pellets were no longer visible. The oxybutynin base was slowly added to the mixing bowl. Mixing was continued for an additional 10 minutes after addition was complete. GMO was heated to 40'C and added very slowly to the mixing bowl. Addition time was approximately 45 minutes. The bowl was then closed and mixing continued for at least 20 minutes before removing the completed oxybutynin mix from the bowl.
  • the oxybutynin mix was calendared to 5 mil thickness between release liners (FCD/polyester) .
  • Five one-foot sections of the oxybutynin film were heat laminated to Medpar ® backing (medium density polyethylene layer/aluminum polyester layer/EVA layer).
  • Three of the oxybutynin film/backing laminates were laminated to 3M acrylate transfer adhesive MSP 1006 P.
  • EXAMPLE 1 The in vitro transdermal oxybutynin permeation rates through the epidermis of two human skin donors from devices described above were determined.
  • the release liner was removed and the oxybutynin-releasing surface was placed against the stratum corneum side of a disc of human epidermis which had been blotted dry just prior to use.
  • the excess epidermis was wrapped around the device so that none of the device edge was exposed to the receptor solution.
  • the device covered with epidermis was attached to the flat side of the Teflon ® holder of a release rate rod using nylon mesh and metal string.
  • the rods were reciprocated in a fixed volume of receptor solution 0.05 M phosphate buffer, pH 6.5.
  • the entire receptor solution was changed at each sampling time.
  • EXAMPLE 2 The in vitro transdermal oxybutynin permeation rates through the epidermis of five human skin donors from devices described above were determined as described in Example 1.
  • the control formulation contained 30 wt % oxybutynin base (no permeation enhancer) in an EVA 40 matrix. No in-line adhesive was present.
  • the other formulation contained 28 wt % oxybutynin base and 28 wt % Myverol ® 18-99K glycerol monooleate in an EVA 40 matrix. There was a 3M acrylate in ⁇ line adhesive present. This same device was used in the in vivo testing described in Examples 3 and 4. The results are summarized in the following table:
  • This experiment was carried out using standard glass diffusion cells which consist of a donor compartment with a 4 ml capacity, and a receptor compartment with a 22 ml capacity.
  • the receptor compartment has both a venting tube (uncapped) and a sampling port (capped).
  • the stratum corneum side of the epidermis faced the donor compartment.
  • An 0-ring was positioned between the epidermis and the donor compartment, and a clamp held the compartments together.
  • the receptor solution 22 ml of 0.05 M phosphate buffer solution, pH 6.5, was added to each receptor compartment.
  • the cells were placed in a temperature controlled water bath shaker at 35 ⁇ C and allowed to come to temperature before the donor solution was added. A total of five donor solutions were tested, and the donor volume was 0.2 ml in each case.
  • the donor solutions tested were oxybutynin saturated in 0.05 M phosphate buffer solution, pH 6.5, oxybutynin saturated in mineral oil, oxybutynin saturated in a solution of 30% ethanol in phosphate buffer, oxybutynin saturated in a solution of 10.6% Myverol 18-99K glycerol monooleate in mineral oil, and oxybutynin saturated in a solution of 10.6% glycerol monolaurate in mineral oil. All donor solutions were at pH 6.5.
  • the receptor solution was removed from the test cell and replaced with an equal volume of fresh receptor solution previously equilibrated at 35'C.
  • the receptor solutions for each time interval were then assayed for oxybutynin, by HPLC (Zorbax Rx-C8, 15 cm x 4.6 mm ID, 5 ⁇ m, 30% acetonitrile/water, 0.06% dimethyloctylamine, 0.03% H 3 P0 4 , 220 nm, 1.0 ml/min), to calculate the permeation rate of oxybutynin through epidermis from the donor solution.
  • the in vivo plasma levels of oxybutynin were measured for two body sites.
  • a 10 cm 2 device was worn on the penis for 10% hours and two 10 cm 2 devices were worn on the inner thigh for 24 hours.
  • a control sample was drawn before applying the systems.
  • the device worn on the penis produced a plasma oxybutynin level of 2.0 ng/mL within 4 hours, and the levels varied between 1.4 and 2.1 ng/mL during the following 6k hours of wearing.
  • the systems worn on the inner thigh produced a plasma oxybutynin concentration of 0.9 ng/mL after 12 hours of wearing, and after 24 hours of wearing the level had reached 1.1 ng/mL.
  • the in vivo plasma oxybutynin concentration were also measured in two additional subjects who each wore two 10 cm 2 systems on the inner thigh.
  • One subject achieved a plasma oxybutynin concentration of 2.0 ng/mL after 9 hours, and the plasma level was 1.7 ng/mL after 24 hours of wearing.
  • the other subject achieved a plasma level of

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to the transdermal administration of oxybutynin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in oxybutynin- and permeation enhancer-transmitting relation with the skin site. The matrix contains sufficient amounts of a permeation enhancer and of oxybutynin, in combination, to continuously administer to the skin for a predetermined period of time the oxybutynin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of oxybutynin together with a skin permeation-enhancing amount of a suitable permeation enhancer.

Description

TRANSDERMAL ADMINISTRATION OF OXYBUTYNIN
FIELD OF THE INVENTION This invention relates the efficacious and safe, controlled transdermal administration of oxybutynin and related compounds for s the treatment of neurogenic bladder disorders.
BACKGROUND OF THE INVENTION
Neurogenic bladder disease is a disorder involving loss of control of urination. The major symptoms of this disease are urinary frequency, urinary retention or incontinence. There are two types of 0 lesions that cause a neurogenic bladder. The first, upper otoneuron lesion, leads to hypertonia and hyperreflexia of the bladder, a spastic condition, giving rise to symptoms of urinary frequency and incontinence. The second lesion, a lower motoneuron lesion, involves hypotonia and hyporeflexia of the bladder. The major symptoms in s this condition are urinary retention, since the voiding reflex has been lost, and incontinence, which occurs when the bladder "leaks", being full to overflowing.
The majority of neurogenic bladder patients have the spastic or hypertonic bladder. The clinician usually attempts to convert the 0 condition of hyperreflexia and hypertonia to hypotonia, thereby treating the primary problem of incontinence. When the condition has .been converted to hypotonia, it can be managed by intermittent catheterization. However, there is a significant population of patients who cannot be converted completely from the hypertonic to 5 the hypotonic condition, and who still find they have to urinate every hour or are incontinent. For these patients, treatment with an anticholinergic drug is necessary. The drug of choice is oxybutynin (4-diethylamino-2-butynylphenylcyclohexylglycolate).
The use of oxybutynin chloride, as approved by the FDA in the United States, is described in the 1992 Physician's Desk Reference, pages 1332 through 1333 with reference to the drug Ditropan® manufactured by Marion Merrell Dow. Oxybutynin is normally administered to human beings orally at relatively high doses (5 mg tablets taken two to four times a day). Oxybutynin has been incorporated into tablets, capsules, granules or pills containing 1-5 mg, preferably 5 mg, of oxybutynin chloride, syrups containing 1-5 mg, preferably 5 mg, of oxybutynin chloride per 5 ml and transdermal compositions (creams or ointments) containing 1-10 weight percent ("wt %") oxybutynin chloride. See, BE 902605.
In U.S. Patent No. 4,747,845, oxybutynin was listed as an agent that could be incorporated into a transdermal synthetic resin matrix system for extended duration drug release, but oxybutynin was not used in the device. In U.S. Patent No. 4,928,680 oxybutynin was given as a pharmacologically active agent suitable for transdermal delivery, but as with the above reference, oxybutynin was not incorporated into the device.
Oxybutynin has been incorporated into a device having a water impermeable barrier layer, a reservoir containing oxybutynin in contact with the inner surface of the barrier layer and a removable protector layer in contact with the other surface of the reservoir. The reservoir is a polyurethane fiber mat impregnated with an aqueous solution containing 25 mg/ml of oxybutynin. The device was placed on a 20 jtim thick polybutadiene film. The non-device carrying surface was in contact with 0.05 M isotonic phosphate buffer solution. The in vitro release rate measured was approximately 12 mg over 24 hours through a 49 cm2 area or 10 μg/cm2/hr. (U.S. Patent No. 4,784,857 and EP 0250 125). In Phar Res, "Development of Transdermal Delivery Systems of Oxybutynin: In-Vivo Bioavailability", P. Keshary et a7., (NY)8 (10 Supp) 1991, p. S205 three types of transdermal delivery systems, using matrix-diffusion controlled and membrane-permeation controlled technologies were discussed. The in vitro permeation rate of about 9, 12 and 12 μg/cm2/hr and in vitro release rates (sink condition) of about 1160, 402 and 57.2 μg/cm2/hr were obtained from Silastic monolithic, acryl c pressure sensitive adhesive matrix and reservoir type delivery systems, respectively. In humans, steady state plasma concentrations of about 1.86 ng/ml were obtained after 6 hours of application of a single 20 cm2 patch of the acrylic pressure sensitive adhesive matrix type.
The transdermal route of administration for drugs and other biologically active agents ("agents") has been proposed for a wide variety of systemically acting and locally acting agents on either a rate-controlled or non rate-controlled basis and is described in numerous technical publications and patents, such as U.S. Patents
3,598,122; 3,598,123; 3,731,683; 3,797,494; 4,031,894; 4,201,211;
4,286,592; 4,314,557; 4,379,454; 4,435,180; 4,588,580; 4,645,502; 4,704,282; 4,788,062; 4,816,258; 4,908,027; 4,943,435; and
5,004,610. The disclosures of the above patents are incorporated herein by reference.
Just as certain drugs can irritate, sensitize or be otherwise toxic, so can permeation enhancers. The use of permeation enhancers for transdermal administration is described in numerous technical publications and patents, such as U.S. Patents Nos. 4,940,586;
4,863,738; 4,820,720; 4,746,515; 4,568,343; 4,405,616;
4,379,454; 4,343,798; 4,335,115; 4,299,826; 4,130,667;
4, 130, 643 ; 4,046,886 ; Briti sh Patent No. 1 ,001 ,949 and Idson, Percutaneous Absorpti on , J . Phar. Sci . , Vol . 64, No . 66 , June 1975 , pp. 901 -924.
Permeation enhancers that are not normally toxic at the concentrations employed in cosmetic or medical compositions may exhibit toxic effects at the higher concentrations required to produce adequate permeation enhancement. No "universal" permeation enhancer has been identified. Instead, the behavior of permeation enhancers is highly idiosyncratic; a permeation enhancer effective for one drug may not be effective with other drugs, including closely related drugs. Often, a permeation enhancer will exacerbate irritation and sensitization problems by allowing high transdermal permeation rates of the drug or permeation enhancer or permitting otherwise impermeable components of the transdermal device to enter the skin.
Many potential permeation enhancers interact adversely with other components of transdermal devices. One major problem is that many potential permeation enhancers are not compatible with medically acceptable contact adhesives. Enhancers may improve the transdermal permeation rate adequately, but not adequately reduce the lag time. The use of a permeation enhancer in any transdermal drug delivery device necessarily complicates the design and development of the device. Permeation enhancers cause compatibility problems throughout the delivery system. Instead of having to characterize the properties of the reservoir compositions, adhesives, and release- controlling materials with respect to just the drug, these materials must now have the proper characteristics with respect to both the drug and the permeation enhancer. Typically, drugs and permeation enhancers have very different physical and chemical properties, and, in most cases, the properties of mixtures of the drug with the permeation enhancer are unknown. For example, permeation enhancers can cause, among other problems, cohesive failure of adhesives and can partition through other components in the system.
As used herein> the term "oxybutynin" is used to designate oxybutynin, acid addition salts of oxybutynin and the related compounds thereof. The preferred active agent according to the present invention is oxybutynin itself. Oxybutynin is a base capable of forming acid addition salts with organic and mineral acids, for example, with hydrochloric acid to form oxybutynin chloride. Preferably, the device of this invention contains oxybutynin as the free base. As used herein, the term "transdermal" delivery or application refers to the delivery or application of oxybutynin by passage through skin, mucosa and/or other body surfaces by topical application.
As used herein, the term "therapeutically effective" amount or rate refers to the amount or rate of oxybutynin needed to effect the desired therapeutic result.
As used herein, the term "monoesters" refers to those monoesters having from 10 to 20 carbon atoms. As used herein, the term "glycerol monooleate" refers to glycerol monooleate itself or a mixture of monoglycerides wherein glycerol monooleate is present in the greatest amount.
As used herein, the term "glycerol monolaurate" refers to glycerol monolaurate itself or a mixture of monoglycerides wherein glycerol monolaurate is present in the greatest amount.
As used herein, the term "glycerol onolinoleate" refers to glycerol monolinoleate itself or a mixture of monoglycerides wherein glycerol monolinoleate is present in the greatest amount. The above summarizes the primary characteristics recognized to date that affect suitability of oxybutynin and a permeation enhancer for transdermal administration. There are undoubtedly others, some of which have not yet been recognized. In order for oxybutynin and a permeation enhancer to be suitable for transdermal administration they must possess the right combination of all of these characteristics, a combination which is quite rare and unpredictable.
SUMMARY OF THE INVENTION According to the present invention, it has been discovered that oxybutynin may be safely and efficaciously administered transdermally, together with a suitable permeation enhancer, preferably a monoglyceride or mixture of monoglycerides of fatty acids with a total monoester content of at least 51%. The invention includes a transdermal drug delivery device containing sufficient amounts of permeation enhancer and of oxybutynin, in combination, to provide systemic administration of oxybutynin through the skin for a predetermined period of time for the oxybutynin to provide an effective therapeutic result.
The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of oxybutynin together with a skin permeation-enhancing amount of a suitable permeation enhancer. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a cross-section through a schematic perspective view of one embodiment of transdermal therapeutic devices according to this invention. FIG. 2 is a cross-section through another embodiment of a transdermal therapeutic device according to this invention.
FIG. 3 is a cross-section through another embodiment of a transdermal therapeutic device according to this invention.
FIG. 4 is a cross-section through yet another embodiment of a transdermal therapeutic device according to this invention.
FIG. 5 shows the oxybutynin permeation rate through the epidermis at 35βC with various permeation enhancers.
DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS According to the present invention, it has been found that oxybutynin may be administered to the human body in a therapeutically effective amount via the transdermal route when it is co-administered with a suitable permeation enhancer. Therapeutic blood levels from DUt 0.5 ng/ml to about 3.0 ng/ml can be obtained from administration rates in the range of 0.08 mg/hr to 0.5 mg/hr.
Representative skin permeation rates of oxybutynin through living human skin are in the range of about 12 μg/cm2/hr to about 40 μg/cm2/hr, depending on the permeation enhancer. Therapeutic blood levels can be achieved within approximately 1-5 hours, and peak blood concentrations are achieved at about 3 hours when the system is worn for 24 hours. The range of desired and achievable system permeation rates of oxybutynin, arriving through the skin from a limited area, is 1-20 mg over a period of 24 hours. The system application is easily adapted for shorter or longer duration treatments, but generally 24 hours is the nominal duration for treatment.
Typical transdermal delivery devices are described in U.S. patent numbers 3,598,122; 3,598,123; 4,286,592; 4,314,557; 4,379,454; 4,559,222; 4,573,995; and 4,849,226, for example. All of these are incorporated herein by reference. The co-administration of oxybutynin and a permeation enhancer as disclosed herein can be accomplished by using transdermal devices of these kinds.
Because of the wide variation in skin permeability from individual and from site to site on the same body, it may be preferable that oxybutynin and the permeation enhancer be administered from a rate-controlled transdermal delivery device. Rate control can be obtained either through a rate-controlling membrane or adhesive or through the other means disclosed in the patents noted above. A certain amount of oxybutynin will bind to the skin, and it is accordingly preferred that the skin-contacting layer of the device include this amount of the agent as a loading dose.
Examples of suitable transdermal delivery devices are illustrated in FIGS. 1, 2 and 3. In the drawings, the same reference numbers are used throughout the different figures to designate the same or similar components. The figures are not drawn to scale.
In FIG. 1, transdermal delivery device 10 comprises a reservoir 12 containing both oxybutynin and a suitable permeation enhancer. Reservoir 12 is preferably in the form of a matrix containing oxybutynin and enhancer dispersed therein. Reservoir 12 is sandwiched between a backing layer 14, which is permeable to water vapor, and an in-line contact adhesive layer 16. Preferably, the backing is a spun-laced polyester, such as Sontara®, a nylon reinforced polyurethane, such as NRU-100-C Flexcon® or a multilaminate film layer, such as EVA/EVA/polyvinyldienefluoride
/EVA/EVA film layer Saranex® Type 52. The device 10 adheres to the surface of the skin 18 by means of the adhesive layer 16. The adhesive layer 16 may optionally contain enhancer and/or oxybutynin. A strippable release liner (not shown in FIG. 1) is normally provided along the exposed surface of adhesive layer 15 and is removed prior to application of device 10 to the skin 18. Optionally, a rate- controlling membrane (not shown) may be present between the reservoir 12 and the adhesive layer 16.
Alternatively, as shown in FIG. 2, transdermal therapeutic device 20 may be attached to the skin or mucosa of a patient by means of an adhesive overlay 22. Device 20 is comprised of a oxybutynin- and permeation enhancer-containing reservoir 12 which is preferably in the form of a matrix containing oxybutynin and the enhancer dispersed therein. A backing layer 14, which is impermeable to oxybutynin, the permeation enhancer and water vapor, is provided adjacent one surface of reservoir 12. Adhesive overlay 22 maintains the device on the skin and may be fabricated together with, or provided separately from, the remaining elements of the device. With certain formulations, the adhesive overlay 22 may be preferable to the in-line contact adhesive 16 as shown in FIG. 1. This is true, for example, where the oxybutynin/enhancer reservoir contains a material which adversely affects the adhesive properties of the in¬ line contact adhesive layer 16. Backing layer 14 is preferably slightly larger than reservoir 12, and in this manner prevents the materials in reservoir 12 from adversely interacting with the adhesive in overlay 22. Optionally, a rate-controlling membrane (not shown in FIG. 2) may be provided on the skin-proximal side of reservoir 12. A strippable release liner 24 is also provided with device 20 and -*s removed just prior to application of device 20 to the skin.
In FIG. 3, transdermal del very device 30 comprises a oxybutynin and permeation enhancer containing reservoir ("oxybutynin reservoir") 12 substantially as described with respect to FIG. 1. Permeation enhancer reservoir ("enhancer reservoir") 26 comprises permeation enhancer dispersed throughout and is substantially free of any undissolved oxybutynin. Enhancer reservoir 26 is preferably made from substantially the same matrix as is used to form oxybutynin reservoir 12. A rate-controlling membrane 28 for controlling the release rate of the permeation enhancer from enhancer reservoir 26 to oxybutynin reservoir 12 is placed between the two reservoirs. A rate-controlling membrane (not shown in FIG. 3) for controlling the release rate of the enhancer from oxybutynin reservoir 12 to the skin may also optionally be utilized and would be present between adhesive layer 16 and reservoir 12. The rate-controlling membrane may be fabricated from permeable, semipermeable or microporous materials which are known in the art to control the rate of agents into and out of delivery devices and having a permeability to the permeation enhancer lower than that of oxybutynin reservoir 12. Suitable materials include, but are not limited to, polyethylene, polyvinyl acetate and ethylene vinyl acetate copolymers.
Superimposed over the permeation enhancer reservoir 26 of device 30 is a backing 14 that is permeable to water vapor. On the skin-proximal side of reservoir 12 are an adhesive layer 16 and a strippable liner 24 which would be removed prior to application of the device 30 to the skin.
In the embodiments of FIGS. 1, 2 and 3, the carrier or matrix material of the reservoirs has sufficient viscosity to maintain its shape without oozing or flowing. If, however, the matrix or carrier is a low viscosity flowable material such as a liquid or a gel, the composition can be fully enclosed in a pouch or pocket, as known to the art from U.S. Pat. No. 4,379,454 (noted above), for example, and as illustrated in FIG. 4. Device 40 shown in FIG. 4 comprises a backing member 14 which serves as a protective cover for the device, imparts structural support, and substantially keeps components in device 40 from escaping the device. Device 40 also includes reservoir 12 which contains the oxybutynin and permeation enhancer and bears on its surface distant from backing member 14 a rate-controlling membrane 28 for controlling the release of oxybutynin and/or permeation enhancer from device 40. The outer edges of backing member 14 overlay the edges of reservoir 12 and are joined along the perimeter with the outer edges of the rate-controlling membrane 28 in a fluid-tight arrangement. This sealed reservoir may be effected by pressure, fusion, adhesion, an adhesive applied to the edges, or other methods known in the art. In this manner, reservoir 12 is contained wholly between backing member 14 and rate-controlling membrane 28. On the skin-proximal side of rate-controlling membrane 28 are an adhesive layer 16 and a strippable liner 24 which would be removed prior to application of the device 40 to the skin.
In an alternative embodiment of device 40 of FIG. 4, reservoir 12 contains the permeation enhancer only and is s substantially free of oxybutynin. The oxybutynin and an additional amount of permeation enhancer are present in adhesive layer 16 which acts as a separate reservoir.
The oxybutynin and the permeation enhancer can be co-extensively administered to human skin or mucosa by direct
:o application to the skin or mucosa in the form of an ointment, gel, cream or lotion, for example, but are preferably administered from a skin patch or other known transdermal delivery device which contains a saturated or unsaturated formulation of oxybutynin and the enhancer. is The formulation may be aqueous or non-aqueous based. The formulation should be designed to deliver the oxybutynin and the permeation enhancer at the necessary release rates. Aqueous formulations typically comprise water or water/ethanol and about 1-2 wt % of a gelling agent, an example being a hydrophilic polymer
20 such as hydroxyethylcellulose or hydroxypropylcellulose. Typical non-aqueous gels are comprised of silicone fluid or mineral oil. Mineral oil-based gels also typically contain 1-2 wt % of a gelling agent such as colloidal silicon dioxide. The suitability of a particular gel depends upon the compatibility of its constituents
?5 with both the oxybutynin and the permeation enhancer and any other components in the formulation.
The reservoir matrix should be compatible with oxybutynin, the permeation enhancer and any carrier therefor. The term "matrix" as used herein refers to a well-mixed composite of ingredients fixed
•o into shape. When using an aqueous-based formulation, the reservoir matrix is preferably a hydrophilic polymer, e.g., a hydrogel . When using a non-aqueous-based formulation, the reservoir matrix is preferably composed of a hydrophobic polymer. Suitable polymeric matrices are well known in the transdermal drug delivery art, and examples are listed in the above-named patents previously incorporated herein by reference.
A typical laminated system would comprise a polymeric membrane and/or matrix such as ethylene vinyl acetate (EVA) copolymers, such as those described in U.S. Pat. No. 4,144,317, preferably having a vinyl acetate (VA) content in the range of from about 9% up to about 60% and more preferably about 28% to about 60% VA. Polyisobutylene/oil polymers containing from 4-25% high molecular weight polyisobutylene and 20-81% low molecular weight polyisobutylene with the balance being an oil such as mineral oil or polybutynes may also be used as the matrix material.
The aforementioned patents describe a wide variety of materials which can be used for fabricating the various layers or components of the transdermal oxybutynin delivery devices according to this invention. This invention therefore contemplates the use of materials other than those specifically disclosed herein, including those which may hereafter become known to the art to be capable of performing the necessary functions.
The amount of oxybutynin present in the therapeutic device and required to achieve an effective therapeutic result depends on many factors, such as the minimum necessary dosage of oxybutynin for the particular indication being treated; the solubility and permeability of the matrix, of the adhesive layer and of the rate-controlling membrane, if present; and the period of time for which the device will be fixed to the skin. The minimum amount of oxybutynin is determined by the requirement that sufficient quantities of oxybutynin must be present in the device to maintain the desired rate of release over the given period of application. The maximum amount for safety purposes is determined by the requirement that the quantity of oxybutynin present cannot exceed a rate of release that reaches toxic levels. The oral lethal dose discovered for rats is 1220 mg/kg.
When a constant oxybutynin delivery rate is desired, the oxybutynin is normally present in the matrix or carrier at a concentration in excess of saturation, the amount of excess being a function of the desired length of the oxybutynin delivery period of the system. The oxybutynin may, however, be present at a level below saturation without departing from this invention as long as oxybutynin is continuously administered to the same skin or mucosa site in an amount and for a period of time sufficient to provide the desired therapeutic rate and delivery profile of oxybutynin delivery.
The permeation enhancer is dispersed through the matrix or carrier, preferably at a concentration sufficient to provide permeation-enhancing amounts of enhancer in the reservoir throughout the anticipated administration period. Where there is an additional, separate permeation enhancer matrix layer as well, as in FIGS. 3 and 4, the permeation enhancer normally is present in the separate reservoir in excess of saturation.
The preferred permeation enhancers of the present invention are a onoglyceride or a mixture of monoglycerides of fatty acids with a total monoester content of at least 51%. Fatty acids may be saturated or unsaturated and straight or chained, and include, for example, 1auric acid, myristic acid, stearic acid, oleic acid, linoleic acid and palmitic acid. Monoglycerides are generally available as a mixture of monoglycerides, with the mixture deriving its name from the monoglyceride present in the greatest amount. Monoglyceride permeation enhancers include, for example, glycerol monooleate, glycerol monolaurate and glycerol monolinoleate. In a more preferred embodiment, the permeation enhancer is glycerol monooleate.
In addition to oxybutynin and a suitable permeation enhancer, which are essential to the invention, the matrix or carrier may also contain dyes, pigments, inert fillers, excipients and other conventional components of pharmaceutical products or transdermal devices known to the art.
In the present invention, oxybutynin is delivered at a therapeutically effective rate (that is, a rate that provides a desired therapeutic effect) and the permeation enhancer is delivered at a permeation-enhancing rate (that is, a rate that provides increased permeability of the application site to the oxybutynin) for a predetermined time period and in the required delivery pattern. A preferred embodiment of the present invention comprises a method of treating any disorder in which it is therapeutic to administer a therapeutically effective amount of one or more of the compounds of the present invention to a patient suffering from such disorder.
Another preferred embodiment of the present invention comprises a method of treating neurogenic bladder disorders, e.g., urinary frequency or incontinence. To be useful in treating a neurogenic bladder disorder, oxybutynin should be present in plasma at levels above about 0.5 ng/ml, preferably at levels above about 1.0 ng/ml and most preferably at levels of about 2.0 ng/ml. To achieve this result, oxybutynin is delivered at a therapeutic rate of at least about 40-200 μg per hour, but typically of at least 80 μg/hr, and more typically at about 80-160 μg/hr, for the treatment period, usually about 24 hours to 7 days.
The administration rate through the skin should be sufficient to minimize the size of the device. The size of the device of this invention can vary from less than 1 cm2 to greater than 200 cm2. typical device, however, will have a size within the range of 5-50 cm2. The delivery device containing the oxybutynin and a permeation enhancer is placed on a user such that the device is delivering oxybutynin in a therapeutically effective amount to the user to treat a neurogenic bladder disorder.
The length of time of oxybutynin presence and the total amount of oxybutynin in the plasma can be changed following the teachings of this invention to provide different treatment regimens. Thus, they can be controlled by the amount of time during which exogenous oxybutynin is delivered transdermally to an individual or animal. The devices of this invention can be designed to effectively deliver oxybutynin for an extended time period of from several hours up to 7 days or longer. Seven days is generally the maximum time limit for application of a single device because the adverse affect of occlusion of a skin site increases with time and the normal cycle of sloughing and replacement of the skin cells occurs in about 7 days. The transdermal therapeutic devices of the present invention are prepared in a manner known in the art, such as by those procedures, for example, described in the transdermal device patents listed previously herein. Having thus generally described the invention, the following specific examples describe preferred embodiments thereof.
DETAILED DESCRIPTION OF EXAMPLES The devices for Example 1 were prepared as follows: A. Formulation without a Permeation Enhancer
A formulation containing 30 wt % oxybutynin base in a matrix of EVA 40 (U.S.I. Chemicals, Illinois) was prepared by dissolving the oxybutynin base and EVA 40 in methylene chloride. The solution was poured onto a sheet of fluorocarbon diacrylate ("FCD")/polyester release liner to dry. The dried material was pressed to 5 mil (a. 0.1 mm) thickness between two sheets of FCD/polyester release liner at 75"C. The resulting film was laminated to a flexible cloth backing (spun laced polyester, 1.3 oz/yd2), and 2.0 cm2 discs were cut from the laminate.
B. Formulations with Permeation Enhancers
Formulations containing oxybutynin base at 30 wt %, and various permeation enhancers glycerol monolaurate, glycerol monooleate, and glycerol monolinoleate) at 25 wt % in a matrix of EVA 40 were prepared by dissolving the oxybutynin base, permeation enhancer and EVA 40 in methylene chloride. The same procedure as described above was then used to make the device.
The glycerol monooleate (GM0) used was Myverol® 18-99K glycerol monooleate (Eastman Kodak Chemicals), which has a glycerol monooleate content of 61% and a total monoester content of 93%, the glycerol monolinoleate (GMLO) used was Myverol® 18-92K glycerol monolinoleate, which has a glycerol monolinoleate content of 68% and a minimum total monoester content of 90%, and the glycerol monolaurate (GML) used was Grindtek® ML 90 glycerol monolaurate, which has a glycerol monolaurate content of 90% and a minimum total monoester content of 90%.
C. Device with In-line Adhesive
Each of the oxybutynin matrix/cloth backing laminates were divided in half, and one half of each was laminated to 3M acylate transfer adhesive MSP 32589 (1.6 mil, an acrylate adhesive with 2-5% acid functionality). Before testing, each final laminate was equilibrated for at least 5 days to allow the enhancer and oxybutynin to partition into the contact adhesive. The edges of the devices with in-line adhesive were masked with polyester tape so that the oxybutynin reservoir edges were not exposed to the epidermis or solutions when they were tested.
The devices for Examples 2, 4 and 5 are prepared as follows:
A. Formulation containing GMO A formulation containing 27 wt % oxybutynin base and 27 wt % GMO (Myverol® 18-99K glycerol monooleate) in a matrix of EVA 40 was prepared using a Brabender Mixer and a 50 cc mixing bowl. The EVA 40 was added to the mixing bowl and mixed until pellets were no longer visible. The oxybutynin base was slowly added to the mixing bowl. Mixing was continued for an additional 10 minutes after addition was complete. GMO was heated to 40'C and added very slowly to the mixing bowl. Addition time was approximately 45 minutes. The bowl was then closed and mixing continued for at least 20 minutes before removing the completed oxybutynin mix from the bowl. The oxybutynin mix was calendared to 5 mil thickness between release liners (FCD/polyester) . Five one-foot sections of the oxybutynin film were heat laminated to Medpar® backing (medium density polyethylene layer/aluminum polyester layer/EVA layer). Three of the oxybutynin film/backing laminates were laminated to 3M acrylate transfer adhesive MSP 1006 P. EXAMPLE 1 The in vitro transdermal oxybutynin permeation rates through the epidermis of two human skin donors from devices described above were determined. For each device tested, the release liner was removed and the oxybutynin-releasing surface was placed against the stratum corneum side of a disc of human epidermis which had been blotted dry just prior to use. The excess epidermis was wrapped around the device so that none of the device edge was exposed to the receptor solution. The device covered with epidermis was attached to the flat side of the Teflon® holder of a release rate rod using nylon mesh and metal string. The rods were reciprocated in a fixed volume of receptor solution 0.05 M phosphate buffer, pH 6.5. The entire receptor solution was changed at each sampling time. The temperature of the receptor solution in the water bath was maintained at 35'C. Results are summarized in the following table:
TABLE 1
EXAMPLE 2 The in vitro transdermal oxybutynin permeation rates through the epidermis of five human skin donors from devices described above were determined as described in Example 1. The control formulation contained 30 wt % oxybutynin base (no permeation enhancer) in an EVA 40 matrix. No in-line adhesive was present. The other formulation contained 28 wt % oxybutynin base and 28 wt % Myverol® 18-99K glycerol monooleate in an EVA 40 matrix. There was a 3M acrylate in¬ line adhesive present. This same device was used in the in vivo testing described in Examples 3 and 4. The results are summarized in the following table:
TABLE 2
Control Without With Permeation Skin Donor Permeation Enhancer Enhancer uq/cm2/hr uo/cm2/hr 1 4.7 15.4
2 3.1 6.8
3 2.6 9.4
4 2.5 4.7
5 2.6 5.4
EXAMPLE 3
This experiment was carried out using standard glass diffusion cells which consist of a donor compartment with a 4 ml capacity, and a receptor compartment with a 22 ml capacity. A circular piece of epidermis was placed in each diffusion cell (permeation area = 1.13 cm2) in a horizontal position between a lower capped receptor compartment and an upper capped donor compartment. The receptor compartment has both a venting tube (uncapped) and a sampling port (capped). The stratum corneum side of the epidermis faced the donor compartment. An 0-ring was positioned between the epidermis and the donor compartment, and a clamp held the compartments together. The receptor solution, 22 ml of 0.05 M phosphate buffer solution, pH 6.5, was added to each receptor compartment. The cells were placed in a temperature controlled water bath shaker at 35βC and allowed to come to temperature before the donor solution was added. A total of five donor solutions were tested, and the donor volume was 0.2 ml in each case. The donor solutions tested were oxybutynin saturated in 0.05 M phosphate buffer solution, pH 6.5, oxybutynin saturated in mineral oil, oxybutynin saturated in a solution of 30% ethanol in phosphate buffer, oxybutynin saturated in a solution of 10.6% Myverol 18-99K glycerol monooleate in mineral oil, and oxybutynin saturated in a solution of 10.6% glycerol monolaurate in mineral oil. All donor solutions were at pH 6.5.
At each time interval, the receptor solution was removed from the test cell and replaced with an equal volume of fresh receptor solution previously equilibrated at 35'C. The receptor solutions for each time interval were then assayed for oxybutynin, by HPLC (Zorbax Rx-C8, 15 cm x 4.6 mm ID, 5 μm, 30% acetonitrile/water, 0.06% dimethyloctylamine, 0.03% H3P04, 220 nm, 1.0 ml/min), to calculate the permeation rate of oxybutynin through epidermis from the donor solution.
As can be seen in Figure 5, glycerol monolaurate and glycerol monolinoleate increased the permeation rate of oxybutynin, whereas ethanol showed the same permeation rate as the donor solution containing no permeation enhancer.
EXAMPLE 4
The in vivo plasma levels of oxybutynin were measured for two body sites. A 10 cm2 device was worn on the penis for 10% hours and two 10 cm2 devices were worn on the inner thigh for 24 hours. A control sample was drawn before applying the systems. The device worn on the penis produced a plasma oxybutynin level of 2.0 ng/mL within 4 hours, and the levels varied between 1.4 and 2.1 ng/mL during the following 6k hours of wearing. The systems worn on the inner thigh produced a plasma oxybutynin concentration of 0.9 ng/mL after 12 hours of wearing, and after 24 hours of wearing the level had reached 1.1 ng/mL.
The in vivo plasma oxybutynin concentration were also measured in two additional subjects who each wore two 10 cm2 systems on the inner thigh. One subject achieved a plasma oxybutynin concentration of 2.0 ng/mL after 9 hours, and the plasma level was 1.7 ng/mL after 24 hours of wearing. The other subject achieved a plasma level of
0.7 ng/mL after 12 hours, and the plasma level was 0.8 ng/mL after 24 hours. EXAMPLE 5
The residual oxybutynin in devices which had been worn by subjects was measured and compared to the oxybutynin content of devices which had not been worn. The results are summarized in the following table:
TABLE 3
Measured Drug Loss Subject # Site (mα/20 cm2/dayl
1 inner thigh 5.8 2 inner thigh 8.6
3 chest 6.7
4 abdomen 7.2
5 penis 19.2
Having thus generally described the present invention and described certain specific embodiments thereof including the embodiments that the applicants consider the best mode of practicing their invention, it will be readily apparent that various modifications to the invention may be made by workers skilled in the art without departing from the scope of this invention which is limited only by the following claims.

Claims

WHAT IS CLAIMED IS:
1. A device for the transdermal administration, at a therapeutically effective rate, of oxybutynin, which device comprises:
5 (a) a reservoir comprising a therapeutically effective amount of oxybutynin and a skin permeation- enhancing amount of a permeation enhancer; (b) a backing on the skin-distal surface of the reservoir; and ia (c) means for maintaining the reservoir in oxybutynin- and permeation enhancer-transmitting relation with the skin.
2. A device according to Claim 1 wherein the permeation enhancer is a monoglyceride or a mixture of monoglycerides of a fatty is acids with a total monoesters content of at least 51%.
3. A device according to Claim 2 wherein the permeation enhancer is glycerol monooleate, glycerol monolaurate or glycerol monolinoleate.
4. A device according to Claim 1 wherein the oxybutynin is 20 administered through the skin at a rate of at least 0.08 mg/hour for a predetermined period of time.
5. A device according to Claim 1 wherein the oxybutynin is administered through the skin at a permeation rate of at least
12 μg/cm2/hr for a predetermined period of time.
25 6. A device according to Claim 1 wherein the backing is permeable to water vapor.
7. A device according to Claim 1 wherein the permeation enhancer is glycerol monooleate and the reservoir further comprises a matrix containing ethylene vinyl acetate copolymer having from about 9% to 60% vinyl acetate.
8. A device according to Claim 6 wherein the means for maintaining the reservoir in relation with the skin comprises an in- s line adhesive layer on the skin-proximal surface of the reservoir.
9. A device for the transdermal administration, at a therapeutically effective rate, of oxybutynin, which device comprises:
(a) a first reservoir comprising a therapeutically :c effective amount of oxybutynin and a skin permeation-enhancing amount of a permeation enhancer;
(b) a second reservoir comprising an excess of the permeation enhancer and substantially free of is oxybutynin;
(c) a rate-controlling membrane between the first reservoir and the second reservoir;
(d) a backing on the skin-distal surface of the second reservoir; and
20 (e) means for maintaining the first and second reservoirs in oxybutynin- and permeation enhancer- transmitting relation with the skin.
10. A device according to Claim 9 wherein the oxybutynin is administered through the skin at a rate of at least 0.08 mg/hour for
25 a predetermined period of time.
11. A device according to Claim 9 wherein the oxybutynin is administered through the skin at a permeation rate of at least
12 μg/cm2/hr for a predetermined period of time.
12. A device according to Claim 9 wherein the backing is 0 permeable to water vaoor.
13. A device according to Claim 9 wherein the means for maintaining the reservoirs in relation with the skin comprises an in¬ line adhesive layer on the skin-proximal surface of the first reservoir.
14. A device according to Claim 9 wherein the first reservoir also is an adhesive layer which functions as the means for maintaining the reservoirs in relation with the skin.
15. A device according to Claim 9 wherein the permeation enhancer is a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%.
16. A device according to Claim 15 wherein the permeation enhancer is glycerol monooleate, glycerol monolaurate or glycerol monolinoleate.
17. A method for the transdermal administration of oxybutynin, which method comprises:
(a) administering oxybutynin at a therapeutically effective rate to an area of skin; and
(b) simultaneously administering a permeation enhancer to the area of skin at a rate which is sufficient to substantially increase the permeability of the area to the oxybutynin.
18. A method according to Claim 17 wherein the permeation enhancer is a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%.
19. A method according to Claim 18 wherein the permeation enhancer is glycerol monooleate, glycerol monolaurate or glycerol monolinoleate.
20. A method according to Claim 17 wherein the oxybutynin is administered through the skin at a rate of at least 0.08 mg/hour for a predetermined period of time.
21. A method according to Claim 17 wherein the oxybutynin is administered through the skin at a permeation rate of at least
12 μg/cm2/hr for a predetermined period of time.
22. A method according to Claim 17 wherein the backing is permeable to water vapor.
23. A method for treating neurogenic bladder disorders, the method comprising the step of placing a oxybutynin transdermal delivery device onto the skin of a person, the oxybutynin transdermal delivery device comprising:
(a) a reservoir comprising oxybutynin in an amount sufficient to provide treatment of symptoms of a neurogenic bladder for a predetermined period of time and a permeation enhancer in a skin permeation-enhancing amount;
(b) a backing on the skin-distal surface of the reservoir; and (c) means for maintaining the reservoir in oxybutynin- and permeation enhancer-transmitting relation with the skin.
24. A method according to Claim 23 wherein the permeation enhancer is a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%.
25. A method according to Claim 24 wherein the permeation enhancer is glycerol monooleate, glycerol monolaurate or glycerol monolinoleate.
26. A method according to Claim 23 wherein the oxybutynin is administered through the skin at a rate of at least 0.08 mg/hour for the predetermined period of time.
27. A method according to Claim 23 wherein the oxybutynin is administered through the skin at a permeation rate of at least
12 μg/cm2/hr for a predetermined period of time.
28. A method according to Claim 23 wherein the backing is permeable to water vapor.
29. A method according to Claim 23 wherein the permeation enhancer is glycerol monooleate and the reservoir further comprises a matrix comprising ethylene vinyl acetate copolymer having from about 9% to 60% vinyl acetate.
30. A method according to Claim 29 wherein the means for maintaining the reservoir in relation with the skin comprises an in- line adhesive layer on the skin-proximal surface of the reservoir.
31. A method for treating neurogenic bladder disorders, the method comprising the step of placing a oxybutynin transdermal delivery device onto the skin of a person, the oxybutynin transdermal delivery device comprising: (a) a first reservoir comprising oxybutynin in an amount sufficient to provide treatment of symptoms of a neurogenic bladder for a predetermined period of time and a permeation enhancer in a skin permeation-enhancing amount; (b) a second reservoir comprising an excess of the permeation enhancer and substantially free of oxybutynin; (c) a rate-controlling membrane between the first reservoir and the second reservoir; (d) a backing on the skin-distal surface of the second reservoir; and (c) means for maintaining the first and second reservoirs in oxybutynin- and permeation enhancer- transmitting relation with the skin.
32. A method according to Claim 31 wherein the oxybutynin is administered through the skin at a rate of at least 0.08 mg/hour for a predetermined period of time.
33. A method according to Claim 31 wherein oxybutynin is administered through the skin at a permeation rate of at least
12 μg/cm2/hr for a predetermined period of time.
34. A method according to Claim 31 wherein the backing is permeable to water vapor.
35. A method according to Claim 31 wherein the means for maintaining the reservoirs in relation with the skin comprises an in¬ line adhesive layer on the skin-proximal surface of the first reservoir.
36. A method according to Claim 31 wherein the first reservoir also is an adhesive layer which functions as the means for maintaining the reservoirs in relation with the skin.
37. A method according to Claim 31 wherein the permeation enhancer is a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%.
38. A device according to Claim 37 wherein the permeation enhancer is glycerol monooleate, glycerol monolaurate or glycerol monolinoleate.
EP93911284A 1992-05-13 1993-05-13 Transdermal administration of oxybutynin Expired - Lifetime EP0767659B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88265292A 1992-05-13 1992-05-13
US882652 1992-05-13
PCT/US1993/004518 WO1993023025A1 (en) 1992-05-13 1993-05-13 Transdermal administration of oxybutynin

Publications (2)

Publication Number Publication Date
EP0767659A1 true EP0767659A1 (en) 1997-04-16
EP0767659B1 EP0767659B1 (en) 1999-10-20

Family

ID=25381055

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93911284A Expired - Lifetime EP0767659B1 (en) 1992-05-13 1993-05-13 Transdermal administration of oxybutynin

Country Status (15)

Country Link
US (2) US5411740A (en)
EP (1) EP0767659B1 (en)
JP (1) JP3786684B2 (en)
KR (1) KR950701516A (en)
AT (1) ATE185694T1 (en)
AU (1) AU666735B2 (en)
CA (1) CA2132865C (en)
DE (1) DE69326848T2 (en)
ES (1) ES2137261T3 (en)
FI (1) FI945311A0 (en)
MX (1) MX9302812A (en)
NO (1) NO944249L (en)
NZ (1) NZ252598A (en)
WO (1) WO1993023025A1 (en)
ZA (1) ZA933349B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900250A (en) 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US5919478A (en) * 1993-06-25 1999-07-06 Alza Corporation Incorporating poly-N-vinyl amide in a transdermal system
WO1995009006A1 (en) * 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
EP0760238B1 (en) * 1994-05-18 2002-04-17 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable preparation for treating urination disorder
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
PT800384E (en) * 1994-12-14 2001-06-29 Enbalt Trading Ltd METHOD FOR PREPARING A PHARMACEUTICAL TABLET
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
SE9501670L (en) * 1995-05-05 1996-06-10 Perstorp Ab Omläggningsset
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
AU4990797A (en) * 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6660295B2 (en) 1997-09-30 2003-12-09 Alza Corporation Transdermal drug delivery device package with improved drug stability
US6267984B1 (en) 1997-12-22 2001-07-31 Alza Corporation Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE69927154T2 (en) * 1998-06-25 2006-06-29 Lavipharm Laboratories, Inc. DEVICE AND METHOD FOR TREATING EFFECTIVE ERRORS
DE69942928D1 (en) 1998-08-27 2010-12-23 Pfizer Health Ab THERAPEUTIC FORMULATION FOR THE ADMINISTRATION OF TOLTERODIN WITH CONTROLLED RELEASE
SE9802864D0 (en) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as an antimuscarinic agent for the treatment of overactive bladder
US6348210B1 (en) 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
CN1331586A (en) 1998-12-18 2002-01-16 阿尔扎有限公司 Transparent transdermal nicotine delivery devices
WO2000059483A2 (en) * 1999-04-01 2000-10-12 Alza Corporation Transdermal drug delivery devices comprising a polyurethane drug reservoir
DE60045153D1 (en) * 1999-04-13 2010-12-09 Hisamitsu Pharmaceutical Co PREPARATIONS FOR PERCUTANEOUS ABSORPTION
CA2387973C (en) 1999-11-11 2009-12-22 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6436428B1 (en) 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
JP2003531157A (en) * 2000-04-26 2003-10-21 ワトソン ファーマシューティカルズ， インコーポレイテッド Minimizing adverse experiences associated with oxybutynin treatment
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US6545046B2 (en) 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
DE10060550C1 (en) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermal therapeutic system for administration of oxybutynin, especially for treatment of bladder dysfunction, having two-phase matrix layer of active agent-containing droplets dispersed in adhesive
ITMI20012060A1 (en) * 2001-10-05 2003-04-05 Recordati Chem Pharm NEW N-ACYLATED HETEROCYCLES
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
DE10224556A1 (en) * 2002-05-31 2004-01-08 Grünenthal GmbH Medicament containing 1-dimethylamino-3- (3-methoxy-phenyl) 2-methyl-pentan-3-ol in various formulations
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US20040043171A1 (en) 2002-08-30 2004-03-04 Audett Jay Douglas Multilaminate backing construction
DE10251256A1 (en) * 2002-11-04 2004-05-13 Novosis Ag Transdermal drug delivery system for oxybutynin
ES2536713T3 (en) 2003-03-12 2015-05-27 Epitome Pharmaceuticals Limited Compositions for lipophilic skin of rapid absorption and uses thereof
WO2004087099A2 (en) * 2003-03-26 2004-10-14 Lavipharm S.A. Methods and devices for holding a composition
DE10315917A1 (en) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Highly pure bases of 3,3-diphenylpropylamine monoesters
DE10315878B4 (en) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Device for transdermal administration of fesoterodine and use
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
EP2216018B1 (en) 2004-10-21 2012-04-04 Durect Corporation Transdermal delivery systems
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
CN101340884A (en) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 Methods for the treatment of hyperhidrosis
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
ATE537826T1 (en) 2006-05-16 2012-01-15 Knopp Neurosciences Inc COMPOSITIONS OF R(+)- AND S(-)-PRAMIPEXOLE AND METHOD FOR THEIR USE
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20100041704A1 (en) * 2007-01-12 2010-02-18 Aberg A K Gunnar Dermal compositions of substituted amides and the use thereof as medication for pain and pruritus
EP2137171A4 (en) * 2007-03-14 2010-05-19 Knopp Neurosciences Inc Synthesis of chirally purified substituted benzothiazole diamines
US8927537B2 (en) * 2007-12-21 2015-01-06 Nuvo Research Inc. Patches, formulations, and associated methods for transdermal delivery of alprazolam and other drugs
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
JP2012530723A (en) * 2009-06-19 2012-12-06 ノップ ニューロサイエンシーズ、インク． Compositions and methods for treating amyotrophic lateral sclerosis
CN103732611B (en) 2011-01-10 2016-06-01 伊沃恩有限公司 The purposes of beta-adrenergic inverse agonist for giving up smoking
WO2013061969A1 (en) * 2011-10-26 2013-05-02 久光製薬株式会社 Oxybutynin-containing transdermal absorption preparation
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014188329A2 (en) 2013-05-20 2014-11-27 Mylan, Inc. Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
RS61539B1 (en) 2013-07-12 2021-04-29 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
ES2813674T3 (en) 2013-08-13 2021-03-24 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
CA2973372A1 (en) 2015-01-09 2016-07-14 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281225A (en) * 1961-07-20
GB1031303A (en) * 1964-01-16 1966-06-02 Boving & Co Ltd Improvements in and relating to hydraulic valves
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4130643A (en) * 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4343798A (en) * 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4474845A (en) * 1982-08-26 1984-10-02 General Motors Corporation Compacted sheet molding compound
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4747845A (en) * 1983-10-17 1988-05-31 Enquay Pharmaceutical Associates Synthetic resin matrix system for the extended delivery of drugs
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
BE902605A (en) * 1985-06-06 1985-09-30 Therabel Res S A N V Medicaments for treating urinary tract disorders - contg. oxybutynin chloride
US4784857A (en) * 1986-06-03 1988-11-15 Smith And Nephew Associated Companies Plc Drug delivery device, its preparation and use
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4865848A (en) * 1987-02-26 1989-09-12 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US5071656A (en) * 1987-03-05 1991-12-10 Alza Corporation Delayed onset transdermal delivery device
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
GB8721659D0 (en) * 1987-09-15 1987-10-21 Smith & Nephew Ass Adhesive coated dressings & applicators
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US4994278A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
JP3243564B2 (en) * 1990-08-20 2002-01-07 リードケミカル株式会社 External patch
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
JP3136413B2 (en) * 1991-02-22 2001-02-19 リードケミカル株式会社 Percutaneous absorption type pollakiuria / urinary incontinence treatment
JPH04273818A (en) * 1991-02-28 1992-09-30 Kissei Pharmaceut Co Ltd Percutaneous administration preparation
PT100502A (en) * 1991-05-20 1993-08-31 Alza Corp PHARMACEUTICAL COMPOSITIONS FOR INCREASING THE CAPACITY OF PERMEACAO IN THE SKIN USING GLYCEROL MONOLINOLEATE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9323025A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds

Also Published As

Publication number Publication date
EP0767659B1 (en) 1999-10-20
FI945311A (en) 1994-11-11
KR950701516A (en) 1995-04-28
CA2132865A1 (en) 1993-11-25
WO1993023025A1 (en) 1993-11-25
NO944249L (en) 1994-11-14
US5411740A (en) 1995-05-02
MX9302812A (en) 1993-11-01
CA2132865C (en) 2003-12-02
AU4247393A (en) 1993-12-13
ATE185694T1 (en) 1999-11-15
AU666735B2 (en) 1996-02-22
US5500222A (en) 1996-03-19
DE69326848T2 (en) 2000-01-27
ES2137261T3 (en) 1999-12-16
DE69326848D1 (en) 1999-11-25
NO944249D0 (en) 1994-11-08
FI945311A0 (en) 1994-11-11
JP3786684B2 (en) 2006-06-14
ZA933349B (en) 1994-06-15
NZ252598A (en) 1997-01-29
JPH08502952A (en) 1996-04-02

Similar Documents

Publication Publication Date Title
US5500222A (en) Transdermal administration of oxybutynin
AU679794B2 (en) Monoglyceride/lactate ester permeation enhancer for oxybutynin
JP2975684B2 (en) Transdermal contraceptive formulations, methods and devices
US5641504A (en) Skin permeation enhancer compositions using glycerol monolinoleate
US5314694A (en) Transdermal formulations, methods and devices
AU657502B2 (en) Transdermal contraceptive formulations, methods and devices
AU677206B2 (en) The use of glycerin in moderating transdermal drug delivery
US5198223A (en) Transdermal formulations, methods and devices
JP2550441B2 (en) Skin permeability promoting composition
JP2010500992A (en) Transcutaneous treatment method and transcutaneous treatment system for Alzheimer's disease
US5900250A (en) Monoglyceride/lactate ester permeation enhancer for oxybutnin
JPH04507256A (en) Biphasic transdermal drug delivery device
WO1994021262A1 (en) Device for the transdermal administration of alprazolam
WO1992020377A1 (en) Skin permeation enhancer compositions using glycerol monolinoleate
US6960353B2 (en) Formulations for the transdermal administration of fenoldopam
EP1229909B1 (en) Transdermal delivery of lasofoxifene
PT907359E (en) RESERVOIRS FOR POLYURETHANE HYDROGEL DRUGS FOR USE IN DRUG ADDICTION DRUG ADMINISTRATION SYSTEMS
EP1100476B1 (en) Formulations for the transdermal administration of fenoldopam

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941017

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19970609

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991020

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991020

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991020

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991020

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991020

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991020

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991020

REF Corresponds to:

Ref document number: 185694

Country of ref document: AT

Date of ref document: 19991115

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69326848

Country of ref document: DE

Date of ref document: 19991125

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2137261

Country of ref document: ES

Kind code of ref document: T3

ITF It: translation for a ep patent filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000120

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000120

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000513

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000513

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20080619

Year of fee payment: 16

Ref country code: DE

Payment date: 20080522

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20080528

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080514

Year of fee payment: 16

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090513

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090602

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20080514

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091201

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090514

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090514

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090513